Literature DB >> 3383987

Effect of probenecid on the elimination and protein binding of ceftriaxone.

K Stoeckel1, V Trueb, U C Dubach, P J McNamara.   

Abstract

The kinetics and binding parameters of ceftriaxone have been characterized in eight normal subjects who received, in sequence, 1.0 g ceftriaxone and 1.0 g ceftriaxone together with 250 and 500 mg probenecid q.i.d. Probenecid increased the total systemic clearance (CLTS) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t1/2T (beta)) fell from 8.1 to 6.5 h. In contrast, the renal clearance of free ceftriaxone (CLFR) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone. The final value of CLFR was attained with the lower dose probenecid, whereas the non-renal clearance of free ceftriaxone (CLFNR) fell progressively from 2.78 to 1.90 ml/min/kg with the increasing probenecid dose. The total decrease in the systemic clearance of free ceftriaxone (CLFS) after the higher dose of probenecid was about 30% (4.87 to 3.57 ml/min/kg). As a consequence of a decreased affinity constant (KA), the average free fraction in plasma (f) was increased by 54% after the low dose and by 74% after the high dose of probenecid. The protein binding interaction between probenecid and ceftriaxone appears to be unique. The results are of limited clinical consequence for ceftriaxone but they emphasise the importance of evaluating the kinetics of the free drug when examining interactions involving probenecid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383987     DOI: 10.1007/bf00614552

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Biliary secretion of methotrexate in rats and its inhibition by probenecid.

Authors:  R E Kates; T N Tozer
Journal:  J Pharm Sci       Date:  1976-09       Impact factor: 3.534

2.  Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications.

Authors:  S Kenwright; A J Levi
Journal:  Lancet       Date:  1973-12-22       Impact factor: 79.321

3.  Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.

Authors:  J J Coffey; F J Bullock; P T Schoenemann
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

4.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Interaction of probenecid with the protein binding of methotrexate.

Authors:  J W Paxton
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

9.  The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.

Authors:  N Baber; L Halliday; R Sibeon; T Littler; M L Orme
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

10.  Effect of ceftizoxime, a new cephalosporin antibiotic, on binding of bilirubin to human serum albumin.

Authors:  H Sakamoto; T Murakawa; T Hirose; M Nishida
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

View more
  10 in total

1.  Comparison of the Pharmacokinetic Profiles of Ceftriaxone Used Alone and Combined with Danhong Injection in Old Rats.

Authors:  Qian Zhang; Jianming Guo; Guoliang Dai; Jianping Li; Lijing Zhu; Shufen He; Yang Zong; Zhishu Tang; Buchang Zhao; Wenzheng Ju; Jinao Duan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans.

Authors:  T B Vree; E W Beneken Kolmer
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 6.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  No effect of probenecid on the renal and biliary clearances of digoxin in man.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

8.  Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

9.  Ceftriaxone disposition in open-heart surgery patients.

Authors:  G L Jungbluth; M T Pasko; T R Beam; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 10.  Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Authors:  Yohannes Hagos; Natascha A Wolff
Journal:  Toxins (Basel)       Date:  2010-08-09       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.